14.05.2013
MagForce to Present at Two Investor Conferences in the US
Berlin, Germany, May 14, 2013 – MagForce AG (Frankfurt, XETRA: MF6), a leading medical technology company in the field of nanomedicine in oncology, announced today that the Company will present at two upcoming investor conferences in the US:
07.05.2013
MagForce AG Receives Further Patent Related to NanoTherm® Therapy
Berlin, Germany, May 7, 2013 – MagForce AG (Frankfurt, XETRA: MF6), a leading medical technology company in the field of nanomedicine in oncology, announced today that the Company has been granted a further European patent for its NanoTherm® therapy, for which the opposition period has now expired.
08.04.2013
MagForce AG Receives BfArM Approval to Start the Post-Marketing Study in Glioblastoma with NanoTherm® Therapy
MagForce AG (Frankfurt, XETRA: MF6), a leading medical technology company in the field of nanomedicine in oncology, announced today that it has received approval from the German Federal Institute for Drugs and Medical Devices (BfArM) to start the post-marketing clinical study in recurrent ...
20.03.2013
MagForce successfully implements capital increase
Berlin, Germany, March 20, 2013 - MagForce AG (Frankfurt, XETRA: MF6), a leading medical device company in the field of nanomedicine with focus on oncology, today anounced that it has successfully completed a capital increase against cash and non-cash contributions including preemptive rights in ...
08.02.2013
MagForce to implement capital increase of up to €33.5 million
Berlin, Germany, February 08, 2013 – MagForce AG (Frankfurt, XETRA: MF6), a leading medical technology company in the field of nanomedicine in oncology, intends to implement a capital increase against cash and noncash contributions including preemptive rights in the total amount of around €33.5 ...
31.01.2013
MagForce starts research project with University of Bremen
Berlin, Germany, January 31, 2013 – MagForce AG (Frankfurt, XETRA: MF6), a leading medical technology company in the field of nanomedicine in oncology, today announced the start of a research project with the University of Bremen, Center for Environmental Research and Sustainable Technology, for ...
25.01.2013
MagForce Shareholders’ Meeting resolves to increase capital by up to €33.5 million
Berlin, Germany, January 25, 2013 – MagForce AG (Frankfurt, XETRA: MF6), a leading medical technology company in the field of nanomedicine in oncology, announced today that the Company’s Shareholders’ Meeting, which took place earlier in the day, approved all agenda items with a majority of votes.
